The Toro Company Declares Regular Quarterly Cash Dividend

BLOOMINGTON, Minn.--(BUSINESS WIRE)-- The Toro Company (NYSE: TTC) today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.34 per share. This dividend is payable on April 19, 2023, to shareholders of record at the close of business on April 6, 2023.

About The Toro Company

The Toro Company (NYSE: TTC) is a leading worldwide provider of innovative solutions for the outdoor environment including turf and landscape maintenance, snow and ice management, underground utility construction, rental and specialty construction, and irrigation and outdoor lighting solutions. With net sales of $4.5 billion in fiscal 2022, The Toro Company’s global presence extends to more than 125 countries through a family of brands that includes Toro, Ditch Witch, Exmark, Spartan Mowers, BOSS Snowplow, Ventrac, American Augers, Trencor, Pope, Subsite Electronics, HammerHead, Radius HDD, Perrot, Hayter, Unique Lighting Systems, Irritrol, and Lawn-Boy. Through constant innovation and caring relationships built on trust and integrity, The Toro Company and its family of brands have built a legacy of excellence by helping customers work on golf courses, sports fields, construction sites, public green spaces, commercial and residential properties and agricultural operations. For more information, visit www.thetorocompany.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230321005925/en/

Investor Relations
Jeremy Steffan
Director, Investor Relations
(952) 887-7962, [email protected]

Media Relations
Branden Happel
Senior Manager, Public Relations
(952) 887-8930, [email protected]

Source: The Toro Company

You May Also Be Interested In

• Game, Set, Pit! Dickey’s Barbecue Launches Mobile Games To Connect with Next Generation of Fans
• Quadravest Preferred Split Share ETF Financial Results to June 30, 2026
• Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study